Advertisement

Topics

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

13:54 EDT 1 Aug 2017 | SCRIP

Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said...

      

Related Stories

 

Original Article: Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

NEXT ARTICLE

More From BioPortfolio on "Exclusive Remicade Contracts Are Slowing Biosimilar Uptake"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...